|
Douglas D. Taylor is an entrepreneur and former academic researcher in the field of extracellular vesicles. Taylor is the Chief Scientific Officer of Aethlon Medical and its wholly owned subsidiary, Exosome Sciences. Taylor attained a bachelor's degree from the University of Richmond and a Ph.D. from Wake Forest University. He was a post-doctoral fellow at Boston University. Taylor was a professor and Vice Chair for Research in the Department of Obstetrics, Gynecology, and Women's Healthheld at the University of Louisville in Kentucky. He was also on the faculty of the University of California, Davis. Taylor first described exosomes in the 1980s, originally believing them to be cell fragments.〔(Todd S. Ing, et al, ''Dialysis: History, Development and Promise'' (Hackensack, New Jersey: World Scientific Publishing, 2012), p. 843 )〕 Taylor is on the editorial board of the ''Journal of Glycobiology'' of OMICS, Inc.,〔(【引用サイトリンク】title=Editorial Board Members -Glycobiology Journals )〕〔http://www.omicsgroup.org/editor-biography/Douglas_Taylor/ OMICS Glycobiology biography〕 a publisher on Beall's list of predatory open access publishers.〔http://scholarlyoa.com/publishers/ Scholarly Open Access〕〔Declan Butler, (''Investigating journals: The dark side of publishing'' ), ''Nature,'' 27 March 2013.〕 In 2015, the ''Journal of Immunology'' retracted a paper it published in 2006 and which Taylor had co-written〔("Pregnancy-Associated Exosomes and Their Modulation of T Cell Signaling," ) ''Journal of Immunology,'' 2006 Feb 1;176(3):1534-42〕 after an institutional research misconduct investigation committee had determined that "multiple figures" in the paper were falsified.〔("Retraction: Pregnancy-Associated Exosomes and Their Modulation of T Cell Signaling," ) ''Journal of Immunology,'' June 15, 2015, vol. 194 no. 12 6190.〕 ==References== 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Douglas D. Taylor」の詳細全文を読む スポンサード リンク
|